Docetaxel /m²

Phase 2Small molecule

AstraZeneca

Docetaxel /m² is one of 144 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

143

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Prostate AdenocarcinomaPhase 1

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Docetaxel /m²

AstraZeneca

Phase 2

2 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

9 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Prostate Adenocarcinoma

NCT07316686

Q2 2027

Phase 3Active, not recruiting

Prostate Cancer

NCT03574571

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Withdrawn·PPeng Wang, MD PhD·Phase 1/2·NCT03343977

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT03574571·732 enrolled

Melanoma1 trial

A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy

Completed·YYonsei University·Phase 2·NCT02223884·30 enrolled

Small Cell Lung Cancer1 trial

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01750281·212 enrolled

Prostate Adenocarcinoma1 trial

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Not yet recruiting·IInstituto do Cancer do Estado de São Paulo·Phase 1·NCT07316686·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Docetaxel /m². U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel /m² compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel /m². EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Docetaxel /m²

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Prostate Cancer2 trials

Melanoma1 trial

Small Cell Lung Cancer1 trial

Prostate Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News